Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.35 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136072 | 0.85 | CNR2 (0.37) | TRPV3CNR2ATRP2RX7PIM3 | |
| SCHEMBL25136154 | 0.85 | CNR2 (0.37) | TRPV3CNR2ATRP2RX7PIM3 | |
| SCHEMBL25136299 | 0.79 | PIM1 (0.46) | CNR2PIM3PIM2PIM1 | |
| SCHEMBL25136288 | 0.78 | CNR2 (0.58) | CNR2ATR | |
| SCHEMBL25136270 | 0.78 | CNR2 (0.58) | CNR2ATR | |
| SCHEMBL25135921 | 0.77 | CNR2 (0.38) | CNR2ATRP2RX7PIM3PIM2 | |
| SCHEMBL25135995 | 0.72 | CNR2 (0.38) | CNR2ATRABL1 | |
| SCHEMBL25136311 | 0.72 | CNR2 (0.38) | CNR2ATRABL1 | |
| SCHEMBL25136062 | 0.72 | ABL1 (0.41) | ABL1HDAC9 | |
| SCHEMBL25135917 | 0.72 | ABL1 (0.41) | ABL1HDAC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | TRPV3 1567/4885CNR2 547/4885ATR 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.